Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma Retraction in /10.3892/ol.2024.14347

Zhou,Peng; Li,Xuemin

doi:10.3892/ol.2019.10331

Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma

Retraction in: /10.3892/ol.2024.14347

Authors:
- Peng Zhou
- Xuemin Li
View Affiliations

Affiliations: Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, P.R. China
Published online on: May 7, 2019 https://doi.org/10.3892/ol.2019.10331
Pages: 307-313
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression of microRNA (miR)‑338‑5p in retinoblastoma(RB), thereby evaluating whether it could have potential as a biomarker to screen patients with RB from healthy controls. The results revealed that miR‑338‑5p was significantly upregulated in patients with RB compared with in healthy controls. There was no significant difference in the expression of miR‑338‑5p between patients with RB of different age, sex, tumor stage or binocular disease. Receiver operator characteristic analysis indicated that serum miR‑338‑5p combined with neuron‑specific enolase (NSE) had a larger area under the curve compared with serum miR‑338‑5p alone when diagnosing RB. In addition, suppression of miR‑338‑5p induced slower proliferation of ACBRI‑181 and Y79 cells at 2, 3, 4 and 5 days compared with the negative control group. Flow cytometric analysis indicated that transfection with miR‑338‑5p inhibitor leads to significant cell cycle arrest in ACBRI‑181 and Y79 cells compared with in the negative control group. Furthermore, transfection with miR‑338‑5p inhibitor significantly decreased ACBRI‑181 and Y79 cell migration and invasion, suggesting that miR‑338‑5p may serve an oncogenic role in the progression of RB. In conclusion, the low expression of miR‑338‑5p in the serum of patients with RB suggests that it may be involved in the formation of RB. Serum miR‑338‑5p has the potential to be a tumor marker of RB, and, in combination with NSE, miR‑338‑5p may improve the early diagnosis rate of RB.

View Figures

View References

1	Giacalone M, Mastrangelo G and Parri N: Point-of-care ultrasound diagnosis of retinoblastoma in the emergency department. Pediatr Emerg Care. 34:599–601. 2018. View Article : Google Scholar : PubMed/NCBI
2	Stathopoulos C, Moulin A, Gaillard MC, Beck-Popovic M, Puccinelli F and Munier FL: Conservative treatment of diffuse infiltrating retinoblastoma: Optical coherence tomography-assisted diagnosis and follow-up in three consecutive cases. Br J Ophthalmol. Jul 26–2018.(Epub ahead of print). doi: 10.1136/bjophthalmol-2018-312546. View Article : Google Scholar : PubMed/NCBI
3	Al-Nawaiseh I, Ghanem AQ and Yousef YA: Familial retinoblastoma: Raised awareness improves early diagnosis and outcome. J Ophthalmol. 2017:50539612017.PubMed/NCBI
4	Jenkinson H: Retinoblastoma: Diagnosis and management-the UK perspective. Arch Dis Child. 100:1070–1075. 2015. View Article : Google Scholar : PubMed/NCBI
5	Fabian ID, Puccinelli F, Gaillard MC, Beck-Popovic M and Munier FL: Diagnosis and management of secondary epipapillary retinoblastoma. Br J Ophthalmol. 101:1412–1418. 2017. View Article : Google Scholar : PubMed/NCBI
6	Dehainault C, Golmard L, Millot GA, Charpin A, Laugé A, Tarabeux J, Aerts I, Cassoux N, Stoppa-Lyonnet D, Gauthier-Villars M and Houdayer C: Mosaicism and prenatal diagnosis options: Insights from retinoblastoma. Eur J Hum Genet. 25:381–383. 2017. View Article : Google Scholar : PubMed/NCBI
7	Parrilla-Vallejo M, Perea-Pérez R, Relimpio-López I, Montero-de-Espinosa I, Rodríguez-de-la-Rúa E, Terrón-León JA, Díaz-Granda MJ, Coca-Gutiérrez L and Ponte-Zuñiga B: Retinoblastoma: The importance of early diagnosis. Arch Soc Esp Oftalmol. 93:423–430. 2018. View Article : Google Scholar : PubMed/NCBI
8	Ramírez-Ortiz MA, Lansingh VC, Eckert KA, Haik BG, Phillips BX, Bosch-Canto V, González-Pérez G, Villavicencio-Torres A and Etulain-González A: Systematic review of the current status of programs and general knowledge of diagnosis and management of retinoblastoma. Bol Med Hosp Infant Mex. 74:41–54. 2017.PubMed/NCBI
9	Shah PK, Sripriya S, Narendran V and Pandian AJ: Prenatal genetic diagnosis of retinoblastoma and report of RB1 gene mutation from India. Ophthalmic Genet. 37:430–433. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wu L, Chen Z and Xing Y: miR-506-3p inhibits cell proliferation, induces cell cycle arrest and apoptosis in retinoblastoma by directly targeting NEK6. Cell Biol Int. Aug 6–2018.(Epub ahead of print). doi: 10.1002/cbin.11041. View Article : Google Scholar
11	Clarke JI, Forootan SS, Lea JD, Howell LS, Rodriguez JM, Kipar A, Goldring CE, Park BK, Copple IM and Antoine DJ: Circulating levels of miR-122 increase post-mortem, particularly following lethal dosing with pentobarbital sodium: Implications for pre-clinical liver injury studies. Toxicol Res (Camb). 6:406–411. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hu HL, Nie ZQ, Lu Y, Yang X, Song C, Chen H, Zhu S, Chen BB, Huang J, Geng S and Zhao S: Circulating miR-125b but not miR-125a correlates with acute exacerbations of chronic obstructive pulmonary disease and the expressions of inflammatory cytokines. Medicine (Baltimore). 96:e90592017. View Article : Google Scholar : PubMed/NCBI
13	Copier CU, León L, Fernández M, Contador D and Calligaris SD: Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. Sci Rep. 7:135142017. View Article : Google Scholar : PubMed/NCBI
14	D'Agostino M, Martino F, Sileno S, Barillà F, Beji S, Marchetti L, Gangi FM, Persico L, Picozza M, Montali A, et al: Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: Implication of a ZEB1-dependent mechanism. Clin Sci (Lond). 131:2397–2408. 2017. View Article : Google Scholar : PubMed/NCBI
15	Bilegsaikhan E, Liu HN, Shen XZ and Liu TT: Circulating miR-338-5p is a potential diagnostic biomarker in colorectal cancer. J Dig Dis. 19:404–410. 2018. View Article : Google Scholar : PubMed/NCBI
16	Xing Z, Yu L, Li X and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 6:532016. View Article : Google Scholar : PubMed/NCBI
17	Long J, Luo J and Yin X: miR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82. Biomed Pharmacother. 102:1195–1202. 2018. View Article : Google Scholar : PubMed/NCBI
18	Li Y, Huang Y, Qi Z, Sun T and Zhou Y: miR-338-5p promotes glioma cell invasion by regulating TSHZ3 and MMP2. Cell Mol Neurobiol. 38:669–677. 2018. View Article : Google Scholar : PubMed/NCBI
19	Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT and Shields JA: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 113:2276–2280. 2006. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Gutierrez-Camino A, Martin-Guerrero I, Dolzan V, Jazbec J, Carbone-Bañeres A, Garcia de Andoin N, Sastre A, Astigarraga I, Navajas A and Garcia-Orad A: Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk. Oncotarget. 9:22907–22914. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wu T, Lin Y and Xie Z: MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma. Biol Res. 51:132018. View Article : Google Scholar : PubMed/NCBI
23	Zakrzewska M, Fendler W, Zakrzewski K, Sikorska B, Grajkowska W, Dembowska-Bagińska B, Filipek I, Stefańczyk Ł and Liberski PP: Altered MicroRNA expression is associated with tumor grade, molecular background and outcome in childhood infratentorial ependymoma. PLoS One. 11:e01584642016. View Article : Google Scholar : PubMed/NCBI